Ultragenyx Pharmaceutical... (RARE)
Ultragenyx Pharmaceutical Statistics
Share Statistics
Ultragenyx Pharmaceutical has 92.5M shares outstanding. The number of shares has increased by 12.16% in one year.
| Shares Outstanding | 92.5M |
| Shares Change (YoY) | 12.16% |
| Shares Change (QoQ) | 0.19% |
| Owned by Institutions (%) | 91.51% |
| Shares Floating | 86.26M |
| Failed to Deliver (FTD) Shares | 1.74K |
| FTD / Avg. Volume | 0.21% |
Short Selling Information
The latest short interest is 4.25M, so 4.6% of the outstanding shares have been sold short.
| Short Interest | 4.25M |
| Short % of Shares Out | 4.6% |
| Short % of Float | 4.92% |
| Short Ratio (days to cover) | 3.94 |
Valuation Ratios
The PE ratio is -6.69 and the forward PE ratio is -8.47. Ultragenyx Pharmaceutical's PEG ratio is 0.28.
| PE Ratio | -6.69 |
| Forward PE | -8.47 |
| PS Ratio | 6.8 |
| Forward PS | 1.4 |
| PB Ratio | 14.92 |
| P/FCF Ratio | -9.03 |
| PEG Ratio | 0.28 |
Enterprise Valuation
Ultragenyx Pharmaceutical Inc. has an Enterprise Value (EV) of 3.35B.
| EV / Earnings | -5.88 |
| EV / Sales | 5.97 |
| EV / EBITDA | -7.14 |
| EV / EBIT | -6.24 |
| EV / FCF | -7.94 |
Financial Position
The company has a current ratio of 2.37, with a Debt / Equity ratio of 0.04.
| Current Ratio | 2.37 |
| Quick Ratio | 2.24 |
| Debt / Equity | 0.04 |
| Total Debt / Capitalization | 3.88 |
| Cash Flow / Debt | -40.22 |
| Interest Coverage | -8.5 |
Financial Efficiency
Return on equity (ROE) is -2.23% and return on capital (ROIC) is -197.17%.
| Return on Equity (ROE) | -2.23% |
| Return on Assets (ROA) | -0.38% |
| Return on Capital (ROIC) | -197.17% |
| Revenue Per Employee | $432,944.36 |
| Profits Per Employee | $-439,863.21 |
| Employee Count | 1,294 |
| Asset Turnover | 0.37 |
| Inventory Turnover | 1.7 |
Taxes
| Income Tax | 1.6M |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -19.04% in the last 52 weeks. The beta is 0.67, so Ultragenyx Pharmaceutical's price volatility has been higher than the market average.
| Beta | 0.67 |
| 52-Week Price Change | -19.04% |
| 50-Day Moving Average | 41.6 |
| 200-Day Moving Average | 47.1 |
| Relative Strength Index (RSI) | 39.28 |
| Average Volume (20 Days) | 828.63K |
Income Statement
In the last 12 months, Ultragenyx Pharmaceutical had revenue of 560.23M and earned -569.18M in profits. Earnings per share was -6.29.
| Revenue | 560.23M |
| Gross Profit | 483.5M |
| Operating Income | -535.97M |
| Net Income | -569.18M |
| EBITDA | -469M |
| EBIT | -535.97M |
| Earnings Per Share (EPS) | -6.29 |
Balance Sheet
The company has 173.73M in cash and 10.3M in debt, giving a net cash position of 163.43M.
| Cash & Cash Equivalents | 173.73M |
| Total Debt | 10.3M |
| Net Cash | 163.43M |
| Retained Earnings | -3.96B |
| Total Assets | 1.5B |
| Working Capital | 472.97M |
Cash Flow
In the last 12 months, operating cash flow was -414.19M and capital expenditures -7.49M, giving a free cash flow of -421.68M.
| Operating Cash Flow | -414.19M |
| Capital Expenditures | -7.49M |
| Free Cash Flow | -421.68M |
| FCF Per Share | -4.66 |
Margins
Gross margin is 86.3%, with operating and profit margins of -95.67% and -101.6%.
| Gross Margin | 86.3% |
| Operating Margin | -95.67% |
| Pretax Margin | -101.31% |
| Profit Margin | -101.6% |
| EBITDA Margin | -83.72% |
| EBIT Margin | -95.67% |
| FCF Margin | -75.27% |
Dividends & Yields
RARE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -16.64% |
| FCF Yield | -12.06% |
Analyst Forecast
The average price target for RARE is $84.5, which is 123.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $84.5 |
| Price Target Difference | 123.5% |
| Analyst Consensus | Buy |
| Analyst Count | 14 |
Scores
| Altman Z-Score | -2.3 |
| Piotroski F-Score | 2 |